Google
EPRX — EUPRAXIA PHARMACEUTICALS INC. COMMON STOCK (Healthcare >> Biotechnology)
EPRX FAQ
What is EPRX's ROE?
EUPRAXIA PHARMACEUTICALS INC. COMMON STOCK reports a Return on Equity (ROE) of -30.74%.
What is EPRX's dividend yield?
EUPRAXIA PHARMACEUTICALS INC. COMMON STOCK offers a dividend yield of 0.00%.
What is EPRX's Deepscope Quality Score?
Deepscope rates EPRX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EPRX?
Deepscope's AI Timing Score for EPRX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EPRX belong to?
EUPRAXIA PHARMACEUTICALS INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.95
Price
-0.50
(-7.75%)
Day Change
|
|
|---|
EPRX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.95 |
| PBV / Sector |
3.03 / 4.63
|
| Earning Per Share | -0.61 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.79 M
GREAT
|
| Average 1W Daily Value |
1.99 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
39% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:24 |
| Symbol | EPRX |
| Name | EUPRAXIA PHARMACEUTICALS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.33 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 413.52 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4
Phone: 250 590 3968
Website: https://www.eupraxiapharma.com
Sector: Healthcare >> Biotechnology
Description: Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
